Atish Dipankar Choudhury, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 24 | 2024 | 11124 | 1.630 |
Why?
|
Chromones | 1 | 2022 | 154 | 0.840 |
Why?
|
Prostate-Specific Antigen | 9 | 2024 | 2494 | 0.650 |
Why?
|
Aniline Compounds | 1 | 2022 | 986 | 0.600 |
Why?
|
Retinoblastoma | 1 | 2019 | 318 | 0.560 |
Why?
|
Antineoplastic Agents, Hormonal | 4 | 2023 | 1524 | 0.560 |
Why?
|
Immunoconjugates | 1 | 2023 | 901 | 0.550 |
Why?
|
Bone Neoplasms | 2 | 2018 | 2529 | 0.460 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2014 | 415 | 0.450 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2938 | 0.430 |
Why?
|
Androgen Receptor Antagonists | 2 | 2023 | 114 | 0.380 |
Why?
|
Adenocarcinoma | 2 | 2021 | 6364 | 0.350 |
Why?
|
Antineoplastic Agents | 6 | 2023 | 13695 | 0.340 |
Why?
|
Prednisone | 3 | 2024 | 1574 | 0.330 |
Why?
|
Urogenital Neoplasms | 2 | 2020 | 137 | 0.320 |
Why?
|
Hormones | 2 | 2023 | 889 | 0.320 |
Why?
|
PTEN Phosphohydrolase | 3 | 2022 | 1142 | 0.280 |
Why?
|
Immunotherapy | 2 | 2020 | 4445 | 0.280 |
Why?
|
Androgen Antagonists | 3 | 2024 | 1377 | 0.260 |
Why?
|
Neoplasms | 3 | 2023 | 21683 | 0.260 |
Why?
|
Prostatectomy | 4 | 2024 | 1890 | 0.250 |
Why?
|
Male | 40 | 2024 | 350118 | 0.250 |
Why?
|
Receptors, Androgen | 3 | 2020 | 1058 | 0.250 |
Why?
|
Ubiquitin-Protein Ligases | 3 | 2018 | 1861 | 0.250 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2023 | 5172 | 0.240 |
Why?
|
Leuprolide | 2 | 2024 | 321 | 0.220 |
Why?
|
BRCA1 Protein | 3 | 2023 | 1149 | 0.220 |
Why?
|
Radium | 1 | 2023 | 65 | 0.210 |
Why?
|
High-Throughput Nucleotide Sequencing | 5 | 2024 | 3597 | 0.210 |
Why?
|
Tissue Extracts | 1 | 2022 | 135 | 0.200 |
Why?
|
Cysteine Endopeptidases | 1 | 2004 | 563 | 0.200 |
Why?
|
Thiohydantoins | 1 | 2021 | 20 | 0.200 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2024 | 241 | 0.200 |
Why?
|
Humans | 49 | 2024 | 744343 | 0.190 |
Why?
|
Neoplasm Metastasis | 4 | 2018 | 4851 | 0.190 |
Why?
|
Multienzyme Complexes | 1 | 2004 | 686 | 0.190 |
Why?
|
Camptothecin | 1 | 2023 | 576 | 0.180 |
Why?
|
Cyclic AMP Response Element-Binding Protein A | 1 | 2019 | 21 | 0.180 |
Why?
|
Ubiquitin | 2 | 2005 | 852 | 0.180 |
Why?
|
Genetic Counseling | 1 | 2023 | 600 | 0.180 |
Why?
|
Cell Cycle | 2 | 2005 | 2967 | 0.170 |
Why?
|
Genes, Retinoblastoma | 1 | 2019 | 136 | 0.170 |
Why?
|
DNA Repair | 3 | 2023 | 2046 | 0.160 |
Why?
|
Administration, Cutaneous | 1 | 2021 | 711 | 0.160 |
Why?
|
Medical Oncology | 2 | 2020 | 2265 | 0.160 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 97 | 0.160 |
Why?
|
Tumor Suppressor Proteins | 2 | 2005 | 2849 | 0.150 |
Why?
|
Neutropenia | 1 | 2023 | 895 | 0.150 |
Why?
|
Androgens | 2 | 2024 | 1281 | 0.150 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2014 | 934 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2020 | 578 | 0.140 |
Why?
|
Estrogen Receptor alpha | 1 | 2020 | 577 | 0.130 |
Why?
|
Urologic Neoplasms | 1 | 2019 | 318 | 0.130 |
Why?
|
Retinoblastoma Protein | 1 | 2019 | 704 | 0.130 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 11524 | 0.130 |
Why?
|
Alkaline Phosphatase | 1 | 2018 | 865 | 0.130 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 973 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2022 | 2503 | 0.120 |
Why?
|
Germ-Line Mutation | 1 | 2022 | 1788 | 0.120 |
Why?
|
Anoikis | 1 | 2014 | 49 | 0.120 |
Why?
|
Video Recording | 1 | 2019 | 949 | 0.120 |
Why?
|
Radiosurgery | 1 | 2023 | 1329 | 0.120 |
Why?
|
Estrogens | 1 | 2021 | 1566 | 0.120 |
Why?
|
Estradiol | 1 | 2021 | 2020 | 0.110 |
Why?
|
Immunoblotting | 1 | 2016 | 1682 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2024 | 9239 | 0.110 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2022 | 2109 | 0.110 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2019 | 808 | 0.110 |
Why?
|
Treatment Outcome | 6 | 2024 | 63114 | 0.110 |
Why?
|
Hemoglobins | 1 | 2018 | 1534 | 0.110 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1758 | 0.100 |
Why?
|
DNA Methylation | 1 | 2024 | 4286 | 0.090 |
Why?
|
Mitosis | 2 | 2005 | 1208 | 0.090 |
Why?
|
Forkhead Transcription Factors | 1 | 2016 | 1613 | 0.090 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 1941 | 0.080 |
Why?
|
Taxoids | 1 | 2012 | 666 | 0.080 |
Why?
|
Survival Analysis | 2 | 2018 | 10252 | 0.080 |
Why?
|
Phenylthiohydantoin | 2 | 2020 | 193 | 0.080 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2012 | 841 | 0.080 |
Why?
|
HeLa Cells | 2 | 2005 | 3128 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 2948 | 0.080 |
Why?
|
Nanotechnology | 1 | 2014 | 710 | 0.080 |
Why?
|
Sarcoma | 1 | 2019 | 1897 | 0.080 |
Why?
|
G2 Phase | 2 | 2005 | 139 | 0.070 |
Why?
|
Immunohistochemistry | 2 | 2019 | 11366 | 0.070 |
Why?
|
Transfection | 2 | 2005 | 5892 | 0.070 |
Why?
|
Cell Line | 4 | 2022 | 15997 | 0.070 |
Why?
|
Registries | 1 | 2022 | 8089 | 0.070 |
Why?
|
Gene Expression Regulation | 1 | 2004 | 12072 | 0.070 |
Why?
|
Genetic Markers | 1 | 2012 | 2634 | 0.070 |
Why?
|
Prognosis | 5 | 2020 | 29063 | 0.070 |
Why?
|
Prostate | 2 | 2023 | 1774 | 0.060 |
Why?
|
Nitriles | 2 | 2020 | 956 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12245 | 0.060 |
Why?
|
Prospective Studies | 5 | 2022 | 53288 | 0.060 |
Why?
|
DNA Damage | 3 | 2020 | 2432 | 0.060 |
Why?
|
Nocodazole | 1 | 2004 | 97 | 0.060 |
Why?
|
Serine | 2 | 2005 | 826 | 0.060 |
Why?
|
Threonine | 1 | 2005 | 279 | 0.060 |
Why?
|
Benzamides | 2 | 2020 | 1379 | 0.060 |
Why?
|
Mitomycin | 1 | 2005 | 259 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2019 | 3143 | 0.060 |
Why?
|
Sulfites | 1 | 2024 | 79 | 0.060 |
Why?
|
Quality of Life | 2 | 2023 | 12804 | 0.060 |
Why?
|
Colorectal Neoplasms | 1 | 2024 | 6773 | 0.060 |
Why?
|
Urogenital System | 1 | 2023 | 86 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5221 | 0.060 |
Why?
|
Dimerization | 1 | 2005 | 893 | 0.060 |
Why?
|
Lutetium | 1 | 2023 | 32 | 0.060 |
Why?
|
DNA Mutational Analysis | 2 | 2017 | 4186 | 0.060 |
Why?
|
S Phase | 1 | 2004 | 423 | 0.060 |
Why?
|
Plasmids | 2 | 2005 | 2307 | 0.050 |
Why?
|
G1 Phase | 1 | 2004 | 415 | 0.050 |
Why?
|
Kidney Neoplasms | 1 | 2019 | 4262 | 0.050 |
Why?
|
Mutation | 7 | 2022 | 29786 | 0.050 |
Why?
|
Heterocyclic Compounds, 1-Ring | 1 | 2023 | 65 | 0.050 |
Why?
|
Radiopharmaceuticals | 1 | 2012 | 2645 | 0.050 |
Why?
|
Immunoprecipitation | 1 | 2005 | 905 | 0.050 |
Why?
|
Macromolecular Substances | 1 | 2005 | 1454 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2024 | 8863 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2023 | 8428 | 0.050 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2023 | 275 | 0.050 |
Why?
|
Cross-Linking Reagents | 1 | 2005 | 694 | 0.050 |
Why?
|
Sequence Analysis | 1 | 2022 | 256 | 0.050 |
Why?
|
Sequence Analysis, DNA | 2 | 2024 | 4803 | 0.050 |
Why?
|
Cell Line, Tumor | 2 | 2016 | 16689 | 0.050 |
Why?
|
Credentialing | 1 | 2022 | 126 | 0.050 |
Why?
|
Neoplasm Proteins | 1 | 2014 | 3703 | 0.050 |
Why?
|
Molecular Targeted Therapy | 1 | 2012 | 2727 | 0.050 |
Why?
|
Neoplasm Staging | 3 | 2020 | 11031 | 0.050 |
Why?
|
Middle Aged | 11 | 2023 | 213383 | 0.050 |
Why?
|
Dipeptides | 1 | 2023 | 409 | 0.050 |
Why?
|
Protease Inhibitors | 1 | 2004 | 791 | 0.050 |
Why?
|
Signal Transduction | 2 | 2022 | 23403 | 0.050 |
Why?
|
RNA, Double-Stranded | 1 | 2021 | 290 | 0.040 |
Why?
|
Genes, BRCA2 | 1 | 2023 | 618 | 0.040 |
Why?
|
Nucleosomes | 1 | 2023 | 494 | 0.040 |
Why?
|
Cell Separation | 1 | 2005 | 1751 | 0.040 |
Why?
|
Preoperative Period | 1 | 2021 | 549 | 0.040 |
Why?
|
BRCA2 Protein | 1 | 2023 | 794 | 0.040 |
Why?
|
Mice | 3 | 2016 | 81183 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 631 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 8642 | 0.040 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2004 | 1338 | 0.040 |
Why?
|
Mass Spectrometry | 1 | 2005 | 2203 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13102 | 0.040 |
Why?
|
Protein Kinases | 1 | 2005 | 1640 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2019 | 793 | 0.040 |
Why?
|
Cell Division | 1 | 2005 | 4568 | 0.040 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2018 | 245 | 0.040 |
Why?
|
Interferons | 1 | 2021 | 706 | 0.040 |
Why?
|
Gene Duplication | 1 | 2018 | 329 | 0.040 |
Why?
|
Genes, myc | 1 | 2018 | 399 | 0.040 |
Why?
|
Phosphorylation | 2 | 2005 | 8436 | 0.040 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2018 | 367 | 0.040 |
Why?
|
Open Reading Frames | 1 | 2019 | 810 | 0.030 |
Why?
|
Kinetics | 1 | 2004 | 6473 | 0.030 |
Why?
|
Breast Neoplasms | 3 | 2020 | 20822 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2004 | 6314 | 0.030 |
Why?
|
Survival Rate | 2 | 2020 | 12788 | 0.030 |
Why?
|
Rare Diseases | 1 | 2020 | 553 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2005 | 6171 | 0.030 |
Why?
|
Disease Progression | 1 | 2012 | 13284 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2004 | 3772 | 0.030 |
Why?
|
Genetic Vectors | 1 | 2005 | 3420 | 0.030 |
Why?
|
Anilides | 1 | 2018 | 408 | 0.030 |
Why?
|
Aged | 7 | 2021 | 163280 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2018 | 671 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2005 | 5974 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 1097 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39050 | 0.030 |
Why?
|
Animals | 3 | 2016 | 168757 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2022 | 3920 | 0.030 |
Why?
|
Phenotype | 2 | 2023 | 16365 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2012 | 12261 | 0.030 |
Why?
|
Testosterone | 1 | 2024 | 2420 | 0.030 |
Why?
|
Gene Dosage | 1 | 2017 | 1252 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2018 | 1179 | 0.030 |
Why?
|
Peptides | 1 | 2005 | 4409 | 0.030 |
Why?
|
Protein Binding | 1 | 2005 | 9386 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2005 | 10943 | 0.030 |
Why?
|
Cerebral Hemorrhage | 1 | 2023 | 2647 | 0.030 |
Why?
|
Haplotypes | 1 | 2018 | 2779 | 0.030 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2014 | 401 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2018 | 1341 | 0.020 |
Why?
|
Genome | 1 | 2020 | 1808 | 0.020 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2004 | 2245 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1813 | 0.020 |
Why?
|
DNA | 1 | 2005 | 7301 | 0.020 |
Why?
|
Alleles | 1 | 2022 | 6933 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2020 | 57776 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6489 | 0.020 |
Why?
|
Genotype | 1 | 2005 | 12951 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2017 | 1988 | 0.020 |
Why?
|
Risk Assessment | 2 | 2021 | 23338 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2018 | 2107 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2004 | 13033 | 0.020 |
Why?
|
Genetic Loci | 1 | 2018 | 2575 | 0.020 |
Why?
|
Female | 7 | 2020 | 380194 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3743 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 5867 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4479 | 0.020 |
Why?
|
Neutrophils | 1 | 2019 | 3719 | 0.020 |
Why?
|
Internet | 1 | 2019 | 3064 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 13989 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2014 | 2699 | 0.020 |
Why?
|
Genomics | 1 | 2022 | 5720 | 0.020 |
Why?
|
Time Factors | 2 | 2005 | 40075 | 0.020 |
Why?
|
Pyridines | 1 | 2018 | 2825 | 0.020 |
Why?
|
Adult | 4 | 2020 | 214055 | 0.020 |
Why?
|
Radiation, Ionizing | 1 | 2005 | 258 | 0.010 |
Why?
|
United States | 2 | 2023 | 69872 | 0.010 |
Why?
|
Cell Survival | 1 | 2014 | 5882 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7279 | 0.010 |
Why?
|
Software | 1 | 2017 | 4443 | 0.010 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2005 | 431 | 0.010 |
Why?
|
Growth Substances | 1 | 2005 | 784 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5535 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2020 | 77449 | 0.010 |
Why?
|
Cytoplasm | 1 | 2005 | 1539 | 0.010 |
Why?
|
Embryo, Mammalian | 1 | 2005 | 1701 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 17446 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2023 | 35421 | 0.010 |
Why?
|
Models, Genetic | 1 | 2005 | 3494 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 56430 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2005 | 4554 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2005 | 9734 | 0.010 |
Why?
|
Stem Cells | 1 | 2005 | 3567 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2005 | 14557 | 0.010 |
Why?
|
Models, Biological | 1 | 2005 | 9583 | 0.000 |
Why?
|